DIVIS LABORATORIES Financial Statement Analysis
|
||
|
The Revenues of DIVIS LABORATORIES have increased by 28.56% YoY .
The Earnings Per Share (EPS) of DIVIS LABORATORIES has decreased by -38.41 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
DIVIS LABORATORIES Last 5 Annual Financial Results
[BOM: 532488|NSE : DIVISLAB]
| Consolidated | Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 |
|---|---|---|---|---|---|
| Revenues | ₹8,960 Cr | ₹6,969 Cr | ₹5,394 Cr | ₹4,946 Cr | ₹3,891 Cr |
| Expenses | ₹5,079 Cr | ₹4,108 Cr | ₹3,571 Cr | ₹3,073 Cr | ₹2,629 Cr |
| Operating Profit (Excl OI) | ₹3,881 Cr | ₹2,861 Cr | ₹1,823 Cr | ₹1,873 Cr | ₹1,263 Cr |
| Other Income | ₹116 Cr | ₹63 Cr | ₹190 Cr | ₹156 Cr | ₹113 Cr |
| Interest | ₹2.00 Cr | ₹2.10 Cr | ₹7.14 Cr | ₹4.68 Cr | ₹2.37 Cr |
| Depreciation | ₹312 Cr | ₹256 Cr | ₹186 Cr | ₹169 Cr | ₹142 Cr |
| Profit Before Tax | ₹3,684 Cr | ₹2,666 Cr | ₹1,819 Cr | ₹1,855 Cr | ₹1,231 Cr |
| Profit After Tax | ₹2,960 Cr | ₹1,984 Cr | ₹1,377 Cr | ₹1,353 Cr | ₹877 Cr |
| Consolidated Net Profit | ₹2,960 Cr | ₹1,984 Cr | ₹1,377 Cr | ₹1,353 Cr | ₹877 Cr |
| Earnings Per Share (Rs) | ₹68.69 | ₹111.53 | ₹74.75 | ₹51.86 | ₹50.96 |
| PAT Margin (%) | 23.32 | 32.94 | 28.38 | 25.23 | 27.15 |
| ROE(%) | 14.89 | 28.16 | 23.90 | 19.30 | 21.00 |
| ROCE(%) | 19.36 | 35.06 | 32.07 | 25.36 | 28.50 |
| Total Debt/Equity(x) | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 |
Key Financials |
||
| Market Cap | : | ₹ 106,873.0 Cr |
| Revenue (TTM) | : | ₹ 7,492.8 Cr |
| Net Profit(TTM) | : | ₹ 1,383.0 Cr |
| EPS (TTM) | : | ₹ 52.1 |
| P/E (TTM) | : | 77.3 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| DIVIS LABORATORIES | 7.8% | 17.4% | 20.3% |
| SUN PHARMACEUTICAL INDUSTRIES | -2.3% | -6.5% | 55.3% |
| CIPLA | 4.1% | -4.8% | 55.6% |
| DR REDDYS LABORATORIES | 4% | 0.8% | 29.4% |
| ZYDUS LIFESCIENCES | -1.2% | -5.2% | 83.9% |
| MANKIND PHARMA | 1.3% | 7% | NA |
| TORRENT PHARMACEUTICALS | 3.9% | 5.1% | 66.1% |
| LUPIN | 0.6% | 0.5% | 127.2% |
| AUROBINDO PHARMA | 5.1% | 10.9% | 87.1% |
DIVIS LABORATORIES Revenues
[BOM: 532488|NSE : DIVISLAB]
| Y-o-Y | 28.56 % |
| 5 Yr CAGR | 23.18 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2023 | ₹8,960 Cr | 28.56 | |
| Mar2022 | ₹6,969 Cr | 29.20 | |
| Mar2021 | ₹5,394 Cr | 9.06 | |
| Mar2020 | ₹4,946 Cr | 27.10 | |
| Mar2019 | ₹3,891 Cr | - | |
DIVIS LABORATORIES Operating Profit
[BOM: 532488|NSE : DIVISLAB]
| Y-o-Y | 35.65 % |
| 5 Yr CAGR | 32.41 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2023 | ₹3,881 Cr | 35.65 | |
| Mar2022 | ₹2,861 Cr | 56.92 | |
| Mar2021 | ₹1,823 Cr | -2.66 | |
| Mar2020 | ₹1,873 Cr | 48.33 | |
| Mar2019 | ₹1,263 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 5.53 % |
| 5 Yr CAGR | 7.49 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2023 | 43.32% | 5.53 | |
| Mar2022 | 41.05% | 21.45 | |
| Mar2021 | 33.8% | -10.75 | |
| Mar2020 | 37.87% | 16.70 | |
| Mar2019 | 32.45% | - | |
DIVIS LABORATORIES Profit After Tax
[BOM: 532488|NSE : DIVISLAB]
| Y-o-Y | 49.19 % |
| 5 Yr CAGR | 35.55 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2023 | ₹2,960 Cr | 49.19 | |
| Mar2022 | ₹1,984 Cr | 44.15 | |
| Mar2021 | ₹1,377 Cr | 1.76 | |
| Mar2020 | ₹1,353 Cr | 54.24 | |
| Mar2019 | ₹877 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | -29.20 % |
| 5 Yr CAGR | -3.73 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2023 | 23.32 % | -29.20 | |
| Mar2022 | 32.94 % | 16.07 | |
| Mar2021 | 28.38 % | 12.49 | |
| Mar2020 | 25.23 % | -7.07 | |
| Mar2019 | 27.15 % | - | |
DIVIS LABORATORIES Earnings Per Share (EPS)
[BOM: 532488|NSE : DIVISLAB]
| Y-o-Y | -38.41 % |
| 5 Yr CAGR | 7.75 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2023 | ₹69 | -38.41 | |
| Mar2022 | ₹112 | 49.20 | |
| Mar2021 | ₹75 | 44.14 | |
| Mar2020 | ₹52 | 1.77 | |
| Mar2019 | ₹51 | - | |
DIVIS LABORATORIES Return on Capital Employed (ROCE)
[BOM: 532488|NSE : DIVISLAB]
| Y-o-Y | -44.78 % |
| 5 Yr CAGR | -9.21 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2023 | 19.36% | -44.78 | |
| Mar2022 | 35.06% | 9.32 | |
| Mar2021 | 32.07% | 26.46 | |
| Mar2020 | 25.36% | -11.02 | |
| Mar2019 | 28.5% | - | |
DIVIS LABORATORIES Share Price vs Sensex
| Current Share Price | : | ₹4,025.4 |
| Current MarketCap | : | ₹ 106,873.0 Cr |
| Updated EOD on | : | Apr 26,2024 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| DIVIS LABORATORIES | 7.8% |
17.4% |
20.3% |
| SENSEX | 0.9% |
1.5% |
23.6% |
DIVIS LABORATORIES related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| S&P BSE HEALTHCARE | 3% | 4% | 55.2% |
| S&P BSE DIVIDEND STABILITY | 2.9% | 4.3% | 58.7% |
| S&P BSE ALLCAP | 2.3% | 5% | 41.4% |
| MFG | 2.1% | 3.8% | 44% |
| S&P BSE 500 | 2.1% | 4.5% | 39.2% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY HEALTHCARE | 3.2% | 2.5% | 51.3% |
| NIFTY PHARMA | 3.2% | 2.2% | 51.4% |
| NSE QUALITY 30 | 2.9% | 2.7% | 35% |
| NIFTY500 MULTICAP 50:25:25 | 2.8% | 6.7% | 49.4% |
| NIFTY200 QUALITY30 | 2.8% | 2% | 32.4% |
You may also like the below Video Courses
FAQ about DIVIS LABORATORIES Financials
How the annual revenues of DIVIS LABORATORIES have changed ?
The Revenues of DIVIS LABORATORIES have increased by 28.56% YoY .
How the Earnings per Share (EPS) of DIVIS LABORATORIES have changed?
The Earnings Per Share (EPS) of DIVIS LABORATORIES has decreased by -38.41 % YoY .
Check out Intrinsic Value of Peers of DIVIS LABORATORIES
Compare Stock Analytics of Peers of DIVIS LABORATORIES
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
